EU and US could reach trade deal this weekend - Reuters
On Monday, Citi analysts, led by Geoff Meacham, adjusted the price target for BioNTech (NASDAQ:BNTX) shares to $140 from the previous target of $145, while retaining a Buy rating for the company. The revision follows BioNTech’s recent financial results which showed top line figures that matched estimates, with revenues reaching €182.8 million, a slight dip of €4.31 million compared to the Bloomberg consensus. However, the company reported a better-than-expected diluted earnings per share (EPS) of -€1.73, outperforming estimates by €0.47 per share, attributed in part to research and development (R&D) expenses that fell below consensus by €90.88 million.
BioNTech’s financial health appears robust, with a significant cash reserve of €15.9 billion recorded at the end of the quarter. InvestingPro analysis confirms this strength, showing the company holds more cash than debt and maintains a healthy current ratio of 7.45, indicating strong liquidity. The company’s diverse oncology portfolio, which includes bispecific antibodies, antibody-drug conjugates (ADCs), and both off-the-shelf and individualized neoantigen therapies, continues to be a point of optimism for Citi analysts. Among the notable developments is the progress of three ongoing, registrational-enabling studies for BN327, an anti-PD-L1/VEGF bispecific, in combination with chemotherapy treatments. Two of these studies have the potential to be the first to market within their class.
The company is also advancing a Biologics License Application (BLA) expected by the end of 2025 for its HER2-directed ADC, which could provide an alternative revenue stream to the company’s Covid-19 vaccine earnings. Despite a stabilization in vaccination trends, Citi notes that the policy environment for respiratory vaccines remains uncertain.
In summary, Citi’s stance on BioNTech is positive, citing the favorable risk/reward profile and considering the current stock valuation as an attractive opportunity for investors. The new price target of $140 reflects a modest adjustment, but the Buy rating remains unchanged, signaling continued confidence in BioNTech’s prospects. Despite a challenging year with revenue decline, InvestingPro data shows the stock has delivered a solid 13% return over the past year. For deeper insights into BioNTech’s valuation and growth prospects, including access to comprehensive Pro Research Reports and additional ProTips, investors can explore InvestingPro’s advanced analytics platform.
In other recent news, BioNTech SE released its financial results for the first quarter of 2025, revealing a revenue shortfall but a narrower loss than analysts had predicted. The company reported revenue of €182.8 million, which fell short of the consensus estimate of €204.08 million. Despite this, BioNTech’s loss per share was €1.73, better than the anticipated €2.00 loss. The revenue decline was attributed to reduced COVID-19 vaccine sales as demand decreased, with revenues primarily driven by the company’s vaccine collaboration. BioNTech’s net loss for the quarter was €415.8 million, an increase from the €315.1 million loss reported in the same period last year, due to higher research and development costs in advancing its oncology pipeline. The company maintained its full-year revenue guidance of €1.7 billion to €2.2 billion. CEO Ugur Sahin emphasized progress in oncology programs, particularly in data updates for their PD-L1xVEGF-A bispecific antibody candidate BNT327 and advancements in clinical evaluations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.